** Shares of Voyager Therapeutics , which develops gene therapy for rare neurological disorders, up 10.5% at $8

** Brokerage Leerink Partners starts coverage of VYGR with "outperform" rating and PT of $15

** Brokerage says Voyager's gene therapy delivery vehicle, known as TRACER, has unique mechanism which makes it stand out from other platforms

** Leerink says VYGR's platform, which is under development for the treatment of rare neurological diseases, has shown improved brain penetration in various animal studies and has high likelihood to be tested in human trials

** Brokerage says cash flow from company's licensing deal for its gene therapy vehicle is significantly underappreciated

** Leerink also sees potential success and more collaborations for company's Alzheimer's disease clinical programs

** 9 of 10 brokerages rate stock "buy" or higher, 1 "hold"; median PT $18 - LSEG

** Including session moves, stock down 10% YTD

(Reporting by Sruthi Narasimha Chari and Bhanvi Satija in Bengaluru)

((sruthinarasimha.chari@thomsonreuters.com))